A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. [electronic resource]
Producer: 20191220Description: 3253-3262 p. digitalISSN:- 1557-3265
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Biomarkers
- Combined Modality Therapy
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Neoplasms -- diagnosis
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- administration & dosage
- Quinolones -- administration & dosage
- Retreatment
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.